Screening

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

Your daily dose of the clinical news you may have missed.

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

Valid and accessible measures are needed to monitor low-value care practices and set benchmarks for de-implementation efforts, researchers reported.

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Your daily dose of the clinical news you may have missed.

Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.